Navidea moves forward with Alzheimer's Dx agent; Neuromodulation predicted to soar;

 @FierceMedDev: ArthroCAD draws Series A for surgical device development. Story | Follow @FierceMedDev

@MarkHFierce: Given Imaging ended exploration of a possible sale or merger--for now, the PillCam maker will go it alone. More | Follow @MarkHFierce

 @DamianFierce: Covidien wants to see if its Hawk devices can work in combo PAD treatment, a potentially lucrative market. Report | Follow @DamianFierce

> Phoenix Cardiac Devices enrolled its first patient in a CE mark-related clinical trial to test a device designed to treat mitral regurgitation without open-heart surgery. Item

> Navidea Biopharmaceuticals ($NAVB) completed another study of its NAV4694 imaging agent, designed to detect beta-amyloid deposits in the brain that can mark Alzheimer's development. The company also expanded its relationship with AstraZeneca ($AZN), licensing two more agents from the drugmaker. More

> Thermo Fisher ($TMO) snagged an expanded CE mark for its QMS Everolimus Assay Kit, clearing the diagnostic for use in liver transplants. The test is already green-lighted for heart and kidney procedures. News

> Pennyslvania's Rex Medical won the FDA's 510(k) clearance for its rotational thrombectomy system. Argon Medical Devices will market the technology in the U.S., European Union, Latin America, Canada and some Asia-Pacific countries. Release

> Venture capital giant Sequoia Capital has helped launch SV Bio, a new diagnostics company that will employ genomic data. Article | Release

> A new report predicts a $6.8 billion global neuromodulation device market by 2017. Story

> Millennium Research expects demand for continuous glucose monitoring devices, insulin pumps and pens to drive moderate growth in the U.S. diabetes care-related medical device market, hitting $16 billion by 2017. Release

Biotech News

 @FierceBiotech: Roche picks Sanford-Burnham chief to revive lagging research group. Story | Follow @FierceBiotech

@JohnCFierce: Looks like Mene Pangalos, champion of virtual development, eliminating fixed costs, comes out on top of AZ R&D. Release | Follow @JohnCFierce

@RyanMFierce: Pharma's got blockbuster hopefuls on the move in 2013, but a special lack of Alzheimer's meds in the mix. More | Follow @RyanMFierce

> Analysts pick the top blockbuster drug prospects in the class of '13. Report

> AstraZeneca research chief Mackay ousted in executive shakeup. News

Pharma News

@FiercePharma: Here's a novel job-preserving approach: U.K. politician urges NHS to use more of $AZN's Brilinta to stave off job cuts. More | Follow @FiercePharma

 @AlisonBFierce:Who gave you the flu? A new Facebook app helps you place the blame. Article | Follow @AlisonBFierce

> Forest's Lexapro plague lingers with 41% hit to Q3 sales. News

> New AZ chief sends top execs packing in management shuffle. Report

Biotech Research News

> Stem cells cut heart damage in muscular dystrophy mice. News

> Targeting VEGF could do more harm than good in the eye. More

> Stem cells show early promise in ALS. Item

Pharma Manufacturing News

> Private equity firm lays out $212 million for API maker. News

> Spain's Idifarma sweats the small stuff. Story

> New manufacturing issues lead AbbVie to 2nd Synthroid recall. Article

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.